Publications of Angelika Erhardt-Lehmann

Naamanka, J.; Tasanko, E.; Trontti, K.; Novak, B.; Suvisaari, J.; Paunio, T.; Vaht, M.; Mattheisen, M.; Meier, S.; Metspalu, A. et al.; Daly, M.; Erhardt-Lehmann, A.; Turck, C. W.; Hartiala, J. A.; Hovatta, I.: GENOME-WIDE ANALYSIS IDENTIFIES SORCS3 AS A NOVEL SUSCEPTIBILITY LOCUS FOR PANIC DISORDER IN THE FINNGEN STUDY. In EUROPEAN NEUROPSYCHOPHARMACOLOGY, 63, p. E101 - E101. (2022)

Erhardt-Lehmann, A.: Stress-induced changes in DNA-methylation: focus on anxiety disorders. In JOURNAL OF NEURAL TRANSMISSION, 128 (11), p. 1798 - 1798. (2021)

Forstner, A. J.; Awasthi, S.; Wolf, C.; Maron, E.; Erhardt, A.; Eriksson, E.; Lavebratt, C.; Allgulander, C.; Woldbye, D. P. D.; Mors, O. et al.; Binder, E. B.; Ruck, C.; Ripke, S.; Deckert, J.; Schumacher, J.: GENOME-WIDE ASSOCIATION STUDY OF PANIC DISORDER. In EUROPEAN NEUROPSYCHOPHARMACOLOGY, 29, p. S776 - S776. 25th World Congress of Psychiatric Genetics (WCPG), Orlando, FL, October 13, 2017 - October 17, 2017. (2019)

Scherf-Clavel, M.; Weber, H.; Deckert, J.; Erhardt-Lehmann, A.: The role of pharmacogenetics in the treatment of anxiety disorders and the future potential for targeted therapeutics. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2021)

Deckert, J.; Erhardt, A.: Predicting treatment outcome for anxiety disorders with or without comorbid depression using clinical, imaging and (epi) genetic data. CURRENT OPINION IN PSYCHIATRY 32 (1), pp. 1 - 6 (2019)